RECURSION PHARMACEUTICALS, INC. (RXRX) FY2026 Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
RECURSION PHARMACEUTICALS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.investing reconciliation → Purchase of an intangible asset: $1,915,000.00investing reconciliation → Purchases of property and equipment: $44,000.00Equity incentive plans → financing reconciliation: $984,000.00financing reconciliation → Repayment of long-term debt and finance lease liabilities: $2,251,000.00Net cash used in operating activities → operating reconciliation: $105,947,000.00Stock-based compensation → operating reconciliation: $19,498,000.00Depreciation and amortization → operating reconciliation: $18,167,000.00Accrued expenses and other current liabilities → operating reconciliation: $5,828,000.00Lease expense → operating reconciliation: $5,216,000.00Prepaid data assets → operating reconciliation: $3,062,000.00Other, net → operating reconciliation: $740,000.00operating reconciliation → Net loss: $131,005,000.00operating reconciliation → Accounts payable: $7,672,000.00operating reconciliation → Unearned revenue: $7,304,000.00operating reconciliation → Other receivables and assets: $6,292,000.00operating reconciliation → Lease liabilities: $4,638,000.00operating reconciliation → Accrued development expense: $1,544,000.00operating reconciliation → Deferred income taxes: $3,000.00Net cash used in financing activities → financing reconciliation: $1,267,000.00Net cash used in investing activities → investing reconciliation: $1,959,000.00Exchange-rate effect → Cash sources and uses: $813,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $665,180,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $556,820,000.00Cash sources and uses → Net cash used in investing activities: $1,959,000.00Cash sources and uses → Net cash used in financing activities: $1,267,000.00Cash sources and uses → Net cash used in operating activities: $105,947,000.00Net loss: -$131,005,000.00Net loss−$131.01 MDepreciation and amortization: $18,167,000.00Depreciation & amortization+$18.17 MStock-based compensation: $19,498,000.00Stock-based compensation+$19.50 MAsset impairment: $0.00Lease expense: $5,216,000.00Non-cash lease expense+$5.22 MLoss on disposal of a business: $0.00Other, net: $740,000.00Other non-cash items+$740.00 KOther receivables and assets: -$6,292,000.00Other operating assets−$6.29 MPrepaid data assets: $3,062,000.00Prepaid data assets+$3.06 MUnearned revenue: -$7,304,000.00Deferred revenue−$7.30 MAccounts payable: -$7,672,000.00Accounts payable−$7.67 MAccrued development expense: -$1,544,000.00Accrued development expense−$1.54 MAccrued expenses and other current liabilities: $5,828,000.00Other accrued liabilities+$5.83 MLease liabilities: -$4,638,000.00Lease liabilities−$4.64 MDeferred income taxes: -$3,000.00Deferred income taxes−$3.00 KAccrued data liability: $0.00Net cash used in operating activities: -$105,947,000.00. Cash required to fund net payments.Operating cash−$105.95 Moperating reconciliation: $158,458,000.00Proceeds from issuance of common shares, net of issuance costs: $0.00Equity incentive plans: $984,000.00Equity incentive plans+$984.00 KRepayment of long-term debt and finance lease liabilities: -$2,251,000.00Debt & capital securities repaid−$2.25 MPurchase of an intangible asset: $0.00Net cash used in financing activities: -$1,267,000.00. Cash required to fund net payments.Financing cash−$1.27 Mfinancing reconciliation: $2,251,000.00Purchases of property and equipment: -$44,000.00PP&E purchases−$44.00 KPurchase of an intangible asset: -$1,915,000.00Intangible asset purchases−$1.92 MDecrease in cash related to disposal of a business: $0.00Purchases of investments: $0.00Net cash used in investing activities: -$1,959,000.00. Cash required to fund net payments.Investing cash−$1.96 Minvesting reconciliation: $1,959,000.00Cash sources and uses: $665,993,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $665,180,000.00Beginning cash$665.18 MEnding cash: Cash, cash equivalents, and restricted cash: $556,820,000.00Ending cash$556.82 MExchange-rate effect: $813,000.00FX effect+$813.00 KCASH RECONCILIATIONInvestingflowsFinancingflowsOperatingflowsNet loss −$131.01M + net operating adjustments $25.06M = operating cash −$105.95MFree cash flow−$105.99 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$108.36 MEnding cash − beginning cash
Chart details

RECURSION PHARMACEUTICALS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
665,180,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
negative 105,947,000 US dollars. Net cash used.
Net loss
negative 131,005,000 US dollars
Depreciation and amortization
18,167,000 US dollars
Stock-based compensation
19,498,000 US dollars
Asset impairment
0 US dollars
Lease expense
5,216,000 US dollars
Loss on disposal of a business
0 US dollars
Other, net
740,000 US dollars
Other receivables and assets
negative 6,292,000 US dollars
Prepaid data assets
3,062,000 US dollars
Unearned revenue
negative 7,304,000 US dollars
Accounts payable
negative 7,672,000 US dollars
Accrued development expense
negative 1,544,000 US dollars
Accrued expenses and other current liabilities
5,828,000 US dollars
Lease liabilities
negative 4,638,000 US dollars
Deferred income taxes
negative 3,000 US dollars
Accrued data liability
0 US dollars
Investing activities
negative 1,959,000 US dollars. Net cash used.
Purchases of property and equipment
negative 44,000 US dollars
Purchase of an intangible asset
negative 1,915,000 US dollars
Decrease in cash related to disposal of a business
0 US dollars
Purchases of investments
0 US dollars
Financing activities
negative 1,267,000 US dollars. Net cash used.
Proceeds from issuance of common shares, net of issuance costs
0 US dollars
Equity incentive plans
984,000 US dollars
Repayment of long-term debt and finance lease liabilities
negative 2,251,000 US dollars
Purchase of an intangible asset
0 US dollars
Operating adjustment reconciliation
158,458,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
2,251,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
1,959,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
813,000 US dollars
Ending cash on Jun 30, 2026
556,820,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
665,993,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 108,360,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 105,947,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
44,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 105,991,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$131.01M + net operating adjustments $25.06M = operating cash −$105.95M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 105,947,000 US dollars minus 44,000 US dollars equals negative 105,991,000 US dollars.
RECURSION PHARMACEUTICALS, INC. (RXRX) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!